Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research note published on Saturday. The firm issued a hold rating on the stock.

Several other equities analysts also recently issued reports on the company. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Shares of Catalent stock opened at $63.48 on Friday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a market cap of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The firm has a fifty day moving average price of $61.37 and a two-hundred day moving average price of $59.96. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business posted ($0.10) EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Analysts expect that Catalent will post 0.78 EPS for the current year.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of Catalent by 15.1% during the third quarter. JPMorgan Chase & Co. now owns 1,520,308 shares of the company’s stock worth $92,085,000 after buying an additional 199,427 shares in the last quarter. Oddo BHF Asset Management Sas bought a new position in Catalent during the 3rd quarter worth $8,480,000. Tidal Investments LLC acquired a new position in Catalent in the 3rd quarter valued at $214,000. Neo Ivy Capital Management bought a new stake in shares of Catalent during the 3rd quarter valued at $1,078,000. Finally, Nomura Asset Management Co. Ltd. grew its holdings in shares of Catalent by 1.4% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock worth $3,211,000 after purchasing an additional 750 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.